Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers

Abstract

Multiple sclerosis (MS) is a demyelinating, inflammatory disease of the central nervous system (CNS), presumably with an autoimmune etiopathogenesis. The first line therapies developed for the relapsing-remitting form of MS (RRMS) include disease modifying treatments (DMTs) as interferons (IFNs) beta and glatiramer acetate (GA) and they are known to be partially effective, with 20 -50% of treated patients experiencing a relapse or disability progression in a short period of time 1 . Natalizumab is a humanized monoclonal antibody that blocks the α-4 integrin, VLA-4, an adhesion molecule present on leukocytes surface, inhibiting their migration into CNS 2 . In the pivotal study AFFIRM, natalizumab reduced annualized relapse rate (aRR) by 68% and the risk of sustained disability progression by 42% over 2 years 2 . Although patients studied in AFFIRM were mostly treatment naïve RRMS patients, natalizumab is only approved for use in patient that failed treatment with DMTs or have highly active disease. This more restricted use of natalizumab is consequence of safety concerns related to risk of progressive multifocal leukoencephalopathy (PML), a rare but potentially life-threatening ABSTRACT Objective: Analyze the demographics, clinical characteristics, efficacy and safety of natalizumab treatment in Brazilian patients with multiple sclerosis (MS) followed up for at least 12 months, in two tertiary MS care centers in São Paulo. Method: We evaluated the effect of natalizumab treatment on annualized relapse rate and disability progression in 75 patients with MS treated with natalizumab for at least 12 months. A subgroup analysis was performed to evaluate efficacy of natalizumab treatment in patients with Expanded Disability Status Scale (EDSS) ≤ 3.0 vs patients with EDSS > 3. Results: Patients treated for at least one year with natalizumab showed a 91% reduction in aRR, as well and an improvement in neurological disability. The impact of natalizumab treatment was greater in patients with EDSS < 3.0. Overall, natalizumab was safe but one patient developed progressive multifocal leukoencephalopathy. Conclusion: Natalizumab as a third line therapy is safe and efficacious, especially in patients with mild neurological disability.Keywords: natalizumab, multiple sclerosis, disability progression, relapse rate. RESUMOObjetivo: Analisar as características clínicas e demográficas, assim como a eficácia e segurança do tratamento com natalizumabe (usado em terceira linha), por no mínimo 12 meses, em pacientes brasileiros acompanhados em dois centros de tratamento de esclerose múltipla, na cidade de São Paulo. Método: Avaliamos o efeito do tratamento com natalizumabe na taxa anualizada de surto (aRR) e progressão de incapacidade (medida por Expanded Disability Status Scale (EDSS)) em 75 pacientes tratados por, no mínimo 12 meses. Realizamos uma análise de subgrupo em pacientes com EDSS ≤ 3,0 e com EDSS > 3, para avaliar o impacto no tratamento, considerando-se o grau de incapacidade neurológica. Resultados: O tratamento com nataliz...

The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study

“…Assessment of patients referred to two Brazilian MS centers showed significant decrease in relapse rate and an improvement of neurological incapacity after 1 year treatment with natalizumab. The effect of this drug was better in patients with lower EDSS scores [9]. Therefore, our results in Iranian MS patients are consistent with the previous studies in other populations.…”

“…Patients were randomly allocated by a medical staff to receive natalizumab (study group, n = 25) or IFN-β (control group, n = 30). Sample size was estimated to be 40 (20 individuals in each group) based on the parameters obtained from Oliveria et al study [9]:…”

Altering the course of disease in multiple sclerosis: many large steps forward

“…In the right hands, for selected patients, natalizumab offers an excellent option for treating MS. This is what is shown in the paper from Oliveira et al 8 published in this issue of Arquivos de Neuropsiquiatria. These authors report on 75 cases of patients with MS who were treated with natalizumab for an average period of two years.…”

MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease

“…111 Although the cutoff may be subjective in clinical practice, previous data suggest that three or more new T2 lesions are associated with a poor prognosis in the short and long term. 112 Previous research showed that the risk of disability progression was increased about 10-fold, 20fold, and 30-fold for one, two, or three or more new T2 lesions, 113 respectively. Another study found that the number of gadoliniumenhancing T1 lesions is the best predictor of disability progression.…”